The raised guidance and strong Q1 beat confirm accelerating momentum in Cortrophin Gel and the generics cash flow engine. With a $100M buyback authorization and net leverage at 1.3x, ANI has ample capacity for further capital deployment. Watch for the Phase 4 gout trial data and the full gout sales force deployment by end of Q2 2026 as key catalysts.
ANIP drugs
ANIP drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 13 $80.88entry
- T+1 · 6mo ago −1.61%α −2.38% · $79.58
- T+5 · 6mo ago −0.69%α +0.47% · $80.32
- T+20 · 5mo ago +0.95%α +1.56% · $81.65
- T+60 · 3mo ago −3.25%α −7.69% · $78.25
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ANI Pharmaceuticals published an updated May 2026 investor presentation via an 8-K (Item 7.01), reiterating and raising its full-year 2026 guidance originally provided on May 8, 2026. The presentation highlights strong Q1 2026 results with total net revenue of $237.5M (+20% YoY) and adjusted non-GAAP EBITDA of $63.0M (+24% YoY), driven by Cortrophin Gel momentum and a new IP license fee. The company raised its 2026 revenue guidance to $1.08B-$1.14B (from $1.055B-$1.115B) and adjusted EBITDA guidance to $285M-$300M (from $275M-$290M), and authorized a new $100M share repurchase program.
Key Facts
- Q1 2026 total net revenue of $237.5M, up 20% YoY from $197.1M
- Q1 2026 adjusted non-GAAP EBITDA of $63.0M, up 24% YoY from $50.7M
- Raised full-year 2026 total net revenue guidance to $1.08B-$1.14B (prior: $1.055B-$1.115B)
- Raised full-year 2026 adjusted non-GAAP EBITDA guidance to $285M-$300M (prior: $275M-$290M)
- Cortrophin Gel net revenue guided to $540M-$575M in 2026, representing ~60% YoY growth
- Board authorized a new $100M share repurchase program
- Out-licensed IP to Harmony Biosciences for $15M upfront fee recognized in Q1 2026, plus up to $10M in milestones
- Cash of $311M as of March 31, 2026; net leverage of ~1.3x
Financial Impact
Raised 2026 revenue guidance by $25M at midpoint ($1.11B vs prior $1.085B) and EBITDA guidance by $10M at midpoint ($292.5M vs prior $282.5M). Q1 revenue grew 20% YoY and EBITDA grew 24% YoY.
Risk Factors
- Cortrophin Gel growth dependent on continued market expansion and gout launch execution
- Blended royalty rate to Merck on Cortrophin Gel expected in high-20% range, pressuring gross margin
- Generics business faces pricing pressure and FDA competition risks
- ILUVIEN return to growth not yet confirmed by hard data
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001023024-26-000054 |
| Document: ani-20260513.htm | 0001023024-26-000054 |
| Document: 0001023024-26-000054-index-headers.html | 0001023024-26-000054 |
| Document: 0001023024-26-000054-index.html | 0001023024-26-000054 |
| Document: 0001023024-26-000054.txt | 0001023024-26-000054 |
Track record
34 reports on ANIP
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +8.88% at T+60 after the Apr 8, 2026 report. 7 of 11 went positive at some point.
Filters
- Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
- Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
- Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
- Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
- Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
- Nov 5, 202617d ago 8-K Bullish 6/10 No price data
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers